Perjeta (pertuzumab)

P2, N=51, Not yet recruiting, Novartis Pharmaceuticals

Nationwide real-world data demonstrate favorable survival outcomes following adoption of dual anti-HER2 therapy. While these findings are broadly consistent with the CLEOPATRA trial, the observational design does not allow direct assessment of equivalence between studies.

P2, N=88, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Jun 2026 --> Jun 2027

P2, N=2175, Active, not recruiting, ECOG-ACRIN Cancer Research Group | Trial primary completion date: Oct 2026 --> Oct 2027

P1/2, N=120, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting

Overall, the available real-world evidence supports the clinical effectiveness of tucatinib-based therapies in HER2+ MBC, including heavily pretreated populations, patients with prior exposure to T-DXd, and those with brain metastases. However, gaps remain in the real-world data regarding the safety profile of tucatinib and its impact on health-related quality of life in routine clinical practice.

Trastuzumab + pertuzumab (TP) was the most commonly used regimen in both neoadjuvant and adjuvant settings. The dual HER2 blockade regimens that were widely adopted in China for HR+/HER2+ early breast cancer have demonstrated effectiveness in improving pCR in routine clinical practice; a longer follow‑up is required to validate survival outcomes. None.

Ultrasensitive ctDNA analyses demonstrated high baseline detection rates and near-universal clearance after abbreviated neoadjuvant therapy, supporting further investigation of ctDNA-guided de-escalation strategies in this setting. ClinicalTrials.gov Identifier: NCT03716180.

P3, N=360, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended

P2, N=48, Active, not recruiting, Carey Anders, M.D. | Trial primary completion date: Apr 2026 --> Nov 2026 | Trial completion date: Jul 2026 --> Nov 2027

In this Romanian single-center cohort, pCR was independently predicted by clinical subtype and a limited set of biological variables, in line with contemporary literature. Although baseline patient-reported outcomes did not improve prediction of pathological response, the high prevalence of pre-treatment anxiety and the emergence of clinical depression during NAC argue for systematic psychosocial screening as part of standard neoadjuvant care.

Neoadjuvant dual HER2 blockade with trastuzumab and pertuzumab plus chemotherapy represents the current standard-of-care for HER2-positive breast cancer. Importantly, Xenium in situ profiling further revealed biological correlates underlying model predictions, including HER2-enriched tumor cell aggregation and neutrophil-helper T-cell interactions, thereby highlighting the mechanistic interpretability of the model. Collectively, HER2-LADDER unites digital pathology and high-resolution spatial profiling into a clinically accessible AI framework, offering a robust, transparent, and biologically grounded tool to tailor individualized HER2-targeted therapy optimization.